Post COVID-19 irritable bowel syndrome. Issue 3 (9th December 2022)

• Record Type: Journal Article
• Authors: Marasco, Giovanni; Cremon, Cesare; Barbaro, Maria Raffaella; Cacciari, Giulia; Falangone, Francesca; Kagramanova, Anna; Bordin, Dmitry; Drug, Vasile; Miftode, Egidia; Fusaroli, Pietro; Mohamed, Salem Youssef; Ricci, Chiara; Bellini, Massimo; Rahman, Mohammed Masudur; Melcarne, Luigi; Santos, Javier; Lobo, Beatriz; Bor, Serhat; Yapali, Suna; Akyol, Deniz; Sapmaz, Ferdane Pirincci; Urun, Yonca Yilmaz; Eskazan, Tugce; Celebi, Altay; Kacmaz, Huseyin; Ebik, Berat; Binicier, Hatice Cilem; Bugdayci, Mehmet Sait; Yağcı, Munkhtsetseg Banzragch; Pullukcu, Husnu; Kaya, Berrin Yalınbas; Tureyen, Ali; Hatemi, İbrahim; Koc, Elif Sitre; Sirin, Goktug; Calıskan, Ali Riza; Bengi, Goksel; Alıs, Esra Ergun; Lukic, Snezana; Trajkovska, Meri; Hod, Keren; Dumitrascu, Dan; Pietrangelo, Antonello; Corradini, Elena; Simren, Magnus; Sjölund, Jessica; Tornkvist, Navkiran; Ghoshal, Uday C; Kolokolnikova, Olga; Colecchia, Antonio; Serra, Jordi; Maconi, Giovanni; De Giorgio, Roberto; Danese, Silvio; Portincasa, Piero; Di Sabatino, Antonio; Maggio, Marcello; Philippou, Elena; Lee, Yeong Yeh; Salvi, Daniele; Venturi, Alessandro; Borghi, Claudio; Zoli, Marco; Gionchetti, Paolo; Viale, Pierluigi; Stanghellini, Vincenzo; Barbara, Giovanni;
• Other Names: author non-byline.; Piacentini Alessio author non-byline.; Shengelia Mariam author non-byline.; Vechorko Valeriy author non-byline.; Cardamone Carla author non-byline.; Rosei Claudia Agabiti author non-byline.; Pancetti Andrea author non-byline.; Rettura Francesco author non-byline.; Pedrosa Marc author non-byline.; Nieto Adoración author non-byline.; Barber Claudia author non-byline.; Henao Alejandro author non-byline.; Campoli Caterina author non-byline.; Mijac Dragana author non-byline.; Korac Milos author non-byline.; Karic Uros author non-byline.; Markovic Aleksandar author non-byline.; Najdeski Ana author non-byline.; Nikolova Dafina author non-byline.; Dimzova Marija author non-byline.; Lior Orly author non-byline.; Shinhar Nadav author non-byline.; Perelmutter Ori author non-byline.; Ringel Yehuda author non-byline.; Sabo Cristina Marica author non-byline.; Chis Ana author non-byline.; Bonucchi Gregorio author non-byline.; Ismaele Caio Giacomo Pietro author non-byline.; Ghirardi Caterina author non-byline.; Marziani Beatrice author non-byline.; Rizzello Barbara author non-byline.; Aguilar Ariadna author non-byline.; Di Paolo Domenica Maria author non-byline.; Bonfrate Leonilde author non-byline.; Marconi Giovanni author non-byline.; Stefano Michele Di author non-byline.; Tagliaferri Sara author non-byline.; Naves Juan Enrique author non-byline.; Galli Andrea author non-byline.; Dragoni Gabriele author non-byline.; Nedelcu Laurentiu author non-byline.; Stevanovic Milena author non-byline.; Nikolovska Ance Volkanovska author non-byline.; Capogreco Antonio author non-byline.; Aghemo Alessio author non-byline.; Mauloni Paula Antonia author non-byline.; Vecchio Sara Del author non-byline.; Rotondo Luca author non-byline.; Capuani Federica author non-byline.; Montanari Davide author non-byline.; Palombo Francesco author non-byline.; Paone Clara author non-byline.; Mastel Giada author non-byline.; Fontana Claudia author non-byline.; Bellacosa Lara author non-byline.; Cogliandro Rosanna F author non-byline.;
• Is Part Of: Gut. Volume 72:Issue 3(2023)
• Page Start: 484
• Page End: 492
• Publication Date: 2022-12-09
• Subjects: COVID-19 -- irritable bowel syndrome; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2022-328483
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objectives: The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut–brain interaction after hospitalisation for SARS-CoV-2 infection. Design: GI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation. Gastrointestinal symptoms, anxiety and depression were assessed using validated questionnaires. Results: The study included 2183 hospitalised patients. The primary analysis included a total of 883 patients (614 patients with COVID-19 and 269 controls) due to the exclusion of patients with pre-existing gastrointestinal symptoms and/or surgery. At enrolment, gastrointestinal symptoms were more frequent among patients with COVID-19 than in the control group (59.3% vs 39.7%, p<0.001). At the 12-month follow-up, constipation and hard stools were significantly more prevalent in controls than in patients with COVID-19 (16% vs 9.6%, p=0.019 and 17.7% vs 10.9%, p=0.011, respectively). Compared with controls, patients with COVID-19 reported higher rates of irritable bowel syndrome (IBS) according to Rome IV criteria: 0.5% versus 3.2%, p=0.045. Factors significantly associated with IBS diagnosis included history of allergies, chronic intake of proton pump inhibitors and presence of dyspnoea. At the 6-month follow-up, the rate of patients with COVID-19 fulfilling the criteria for depression was higher than among controls. Conclusion: Compared with controls, hospitalised patients with COVID-19 had fewer problems of constipation and hard stools at 12 months after acute infection. Patients with COVID-19 had significantly higher rates of IBS than controls. Trial registration number: NCT04691895 .